Longtime biotech vet Andrew Hirsch is taking the top job at C4 — and he clearly has some big plans
Four years after Andrew Hirsch tied the last loose end on Bind’s bankruptcy package and shipped to Agios as its CFO, he is back at the helm.
After the market closed on Tuesday, we learned that Hirsch is taking the CEO post at C4 Therapeutics, which is making every effort necessary to do the window dressing for a major league biotech IPO. He’s taking the place of Andrew Phillips, who hit the exit 2 years after he was promoted from CSO to CEO.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.